文献速递流行病学与生物统计真实世界研究与卫生经济

FDA修正法案与试验注册、发表及结局报告的关联

Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
PubMed 文献 · Trials · 2017-07-18

该研究利用ClinicalTrials.gov、FDA文件与PubMed数据,分析2005至2014年支持FDA批准心血管病与糖尿病新药的183项疗效试验。结果显示,FDAAA实施后试验注册率、发表率及与FDA审评者解读一致的结局报告率均较实施前提高。

要点

  • FDAAA实施后试验注册率78/78(100%) vs 实施前73/105(70%),p<0.001。
  • FDAAA实施后发表率76/78(97%) vs 实施前93/105(89%),p=0.03。
  • FDAAA实施后与FDA审评者解读一致的报告率74/76(97%) vs 实施前78/93(84%),p=0.004。

核心结论

  • FDAAA与支持FDA批准心血管病和糖尿病新药的试验在注册、发表及与FDA解读一致的结局报告方面的增加相关。

研究设计与样本

  • 利用ClinicalTrials.gov、FDA文件与PubMed公开数据,分析2005至2014年支持FDA批准心血管病和糖尿病新药的所有疗效试验,比较FDAAA实施前后情况。
  • 共纳入FDA基于183项试验批准的30种药物、32个适应证,中心每适应证试验数5.7(IQR,3-8)。

主要发现

  • FDAAA实施后试验注册78/78(100%) vs 实施前73/105(70%),p<0.001。
  • FDAAA实施后发表76/78(97%) vs 实施前93/105(89%),p=0.03。
  • FDAAA实施后与FDA审评者解读一致的报告74/76(97%) vs 实施前78/93(84%),p=0.004。
  • FDAAA实施前FDA审评者将80项(76%)试验解读为阳性,其中91项(98%)以阳性发表。
  • FDAAA实施后FDA审评者将71项(91%)试验解读为阳性,其中71项(93%)以阳性发表。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Selective clinical trial publication and outcome reporting has the potential to bias the medical literature. The 2007 Food and Drug Administration (FDA) Amendment Act (FDAAA) mandated clinical trial registration and outcome reporting on ClinicalTrials.gov, a publicly accessible trial registry. METHODS: Using publicly available data from ClinicalTrials.gov, FDA documents, and PubMed, we determined registration, publication, and reporting of findings for all efficacy trials supporting FDA approval of new drugs for cardiovascular disease and diabetes between 2005 and 2014, before and after the FDAAA. For published trials, we compared the published interpretation of the findings (positive, equivocal, or negative) with the FDA reviewer's interpretation. RESULTS: Between 2005 and 2014, the FDA approved 30 drugs for 32 indications of cardiovascular disease (n = 17) and diabetes (n = 15) on the basis of 183 trials (median per indication 5.7 (IQR, 3-8)). Compared with pre FDAAA, post-FDAAA studies were more likely to be registered (78 of 78 (100%) vs 73 of 105 (70%); p < 0.001), to be published (76 of 78 (97%) vs 93 of 105 (89%); p = 0.03), and to present findings concordant with the FDA reviewer's interpretation (74 of 76 (97%) vs 78 of 93 (84%); p = 0.004). Pre FDAAA, the FDA reviewer interpreted 80 (76%) trials as positive and 91 (98%) were published as positive. Post FDAAA, the FDA reviewer interpreted 71 (91%) trials as positive and 71 (93%) were published as positive. CONCLUSIONS: FDAAA was associated with increased registration, publication, and FDA-concordant outcome reporting for trials supporting FDA approval of new drugs for cardiovascular disease and diabetes.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Phillips AT, Desai NR, Krumholz HM, et al. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. Trials. 2017. PMID: 28720112. doi:10.1186/s13063-017-2068-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。